Segall Bryant & Hamill LLC Lowers Stock Position in Bioventus Inc. (NYSE:BVS)

Segall Bryant & Hamill LLC cut its holdings in Bioventus Inc. (NYSE:BVS - Free Report) by 85.9% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 49,547 shares of the company's stock after selling 303,082 shares during the period. Segall Bryant & Hamill LLC owned approximately 0.06% of Bioventus worth $453,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of BVS. Bank of New York Mellon Corp raised its position in Bioventus by 37.4% in the fourth quarter. Bank of New York Mellon Corp now owns 125,055 shares of the company's stock worth $1,313,000 after purchasing an additional 34,036 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in Bioventus by 11.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 435,344 shares of the company's stock worth $4,571,000 after purchasing an additional 45,182 shares in the last quarter. Raymond James Financial Inc. acquired a new position in Bioventus in the fourth quarter worth about $171,000. HighTower Advisors LLC raised its position in Bioventus by 11.3% in the fourth quarter. HighTower Advisors LLC now owns 13,617 shares of the company's stock worth $143,000 after purchasing an additional 1,380 shares in the last quarter. Finally, Swiss National Bank acquired a new stake in shares of Bioventus during the fourth quarter worth approximately $740,000. 62.94% of the stock is currently owned by institutional investors.

Bioventus Trading Up 0.5%

NYSE:BVS traded up $0.03 during trading hours on Wednesday, reaching $6.47. The company's stock had a trading volume of 404,620 shares, compared to its average volume of 430,506. The firm has a market capitalization of $531.47 million, a price-to-earnings ratio of -10.61 and a beta of 0.84. The firm has a 50-day simple moving average of $6.68 and a 200-day simple moving average of $8.28. Bioventus Inc. has a 1 year low of $6.02 and a 1 year high of $14.38. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Craig Hallum set a $15.00 price objective on shares of Bioventus and gave the company a "buy" rating in a research note on Wednesday, May 7th. Cantor Fitzgerald assumed coverage on shares of Bioventus in a research report on Monday, July 7th. They set an "overweight" rating and a $12.00 price target on the stock.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.